| Literature DB >> 30261631 |
Nikolai S Li-Zhulanov1,2, Alexandra L Zakharenko3, Arina A Chepanova4, Jinal Patel5, Ayesha Zafar6, Konstantin P Volcho7,8, Nariman F Salakhutdinov9,10, Jóhannes Reynisson11, Ivanhoe K H Leung12, Olga I Lavrik13,14.
Abstract
Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a DNA repair enzyme that mends topoisomerase 1-mediated DNA damage. Tdp1 is a current inhibition target for the development of improved anticancer treatments, as its inhibition may enhance the therapeutic effect of topoisomerase 1 poisons. Here, we report a study on the development of a novel class of Tdp1 inhibitors that is based on the octahydro-2H-chromene scaffold. Inhibition and binding assays revealed that these compounds are potent inhibitors of Tdp1, with IC50 and KD values in the low micromolar concentration range. Molecular modelling predicted plausible conformations of the active ligands, blocking access to the enzymatic machinery of Tdp1. Our results thus help establish a structural-activity relationship for octahydro-2H-chromene-based Tdp1 inhibitors, which will be useful for future Tdp1 inhibitor development work.Entities:
Keywords: DNA repair enzyme; Tdp1 inhibitor; anticancer agent; biochemical assay; chemical space; molecular modeling; structural-activity relationships; synthesis
Mesh:
Substances:
Year: 2018 PMID: 30261631 PMCID: PMC6222798 DOI: 10.3390/molecules23102468
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of reported Tdp1 inhibitors 1–6, commercial Tdp1 inhibitor Furamidine, and octahydro-2H-chromen-4-ol derivatives 7 that we investigated in this study.
Scheme 1Synthesis of (4)-9 and (4)-9 compounds and proposed mechanism for the synthesis of 4 and 4, as proposed by Nazimova et al. [18].
Scheme 2Synthesis of 10–13 amide derivatives of octahydro-2H-chromen-4-ol.
Inhibitory Potency (IC50) and Binding Affinity (KD) of Compounds 8–13 Against Tdp1.
| Compound | IC50, µM | |||||
|---|---|---|---|---|---|---|
|
| ( | ( | ( | ( | ||
|
|
| NO2- | >15 | >15 | 30.6 ± 9.3 | 23.3 ± 7.4 |
|
| NH2- | >15 | >15 | n.d. | n.d. | |
|
|
| CH3- | 5.8 ± 3.0 | 2.9 ± 0.8 | n.d. | n.d. |
|
| CF3- | 1.4 ± 0.3 | 4.0 ± 0.4 | 2.0 ± 1.2 | 19.8 ± 2.4 | |
|
|
| 5.0 ± 1.5 | 3.3 ± 0.2 | 24.5 ± 5.7 | n.d. | |
|
|
| 1.24 ± 0.02 | 2.8 ± 0.6 | 17.9 ± 3.4 | 12.4 ± 7.5 | |
|
| 1.2 ± 0.3 | n.d. | ||||
* Furamidine was used as a positive control. n.d. = not determined.
Results of the Scoring Functions (GS, CS, ChemPLP, and ASP) for Compounds 8–17 with Tdp1. The IC50 Values of Compounds 8–13 with Tdp1 were Also Included.
| Compound | GS | CS | ChemPLP | ASP | IC50 (μM) |
|---|---|---|---|---|---|
| ( | 40.1 | 26.0 | 47.9 | 27.4 | >15 |
| ( | 41.0 | 25.3 | 45.0 | 26.6 | >15 |
| ( | 41.5 | 25.0 | 41.1 | 27.2 | >15 |
| ( | 42.2 | 25.5 | 45.5 | 29.0 | >15 |
| ( | 42.3 | 25.9 | 50.7 | 28.9 | 2.9 ± 0.8 |
| ( | 44.0 | 25.2 | 49.4 | 28.4 | 5.8 ± 3.0 |
| ( | 39.6 | 23.8 | 51.8 | 34.4 | 4.0 ± 0.4 |
| ( | 44.0 | 25.2 | 50.6 | 31.3 | 1.4 ± 0.3 |
| ( | 55.8 | 30.3 | 57.2 | 29.1 | 3.3 ± 0.2 |
| ( | 56.0 | 30.8 | 56.4 | 29.8 | 5.0 ± 1.5 |
| ( | 51.5 | 32.3 | 57.1 | 30.5 | 2.8 ± 0.6 |
| ( | 52.5 | 31.4 | 56.1 | 30.4 | 1.24 ± 0.02 |
| ( | 60.9 | 30.9 | 60.4 | 31.3 | - |
| ( | 62.5 | 29.6 | 61.3 | 32.8 | - |
| ( | 50.2 | 30.5 | 64.8 | 32.6 | - |
| ( | 53.6 | 28.2 | 59.6 | 28.5 | - |
| ( | 48.7 | 23.2 | 51.6 | 25.9 | - |
| ( | 48.8 | 21.5 | 48.5 | 27.5 | - |
| ( | 49.2 | 21.9 | 49.3 | 25.1 | - |
| ( | 51.2 | 22.2 | 47.9 | 27.7 | - |
Figure 2Docked configurations of derivative (4)-13 to the substrate binding sites predicted by the ChemPLP algorithm. The protein surface is rendered where partial positive, negative charges, and neutral regions are colored blue, red, and grey, respectively (A). The hydrogen bond interactions are depicted as green lines between compound (4)-13 and the amino acids residues; Ser459 and Gly458 (B). Furthermore, lipophilic contacts (LC) are shown as purple dashed lines with His263, Tyr204, Ala520, Ala521, and Pro461.
Figure 3The numeration of the atoms of 8–13 in NMR spectra.